research

Update from the Dean – May 2019

Dear UCSF School of Pharmacy Family and Friends:

At the UCSF School of Pharmacy we don’t just embrace change, we create it. We have a rich history as drivers of change in our profession, in science, and in education. That passion for change, coupled with a scientific mindset, is clearly evident...

2019 Koda-Kimble Seed Award supports School of Pharmacy’s boldest ideas

The 2019 Mary Anne Koda-Kimble Seed Award for Innovation will fund nine bold research projects, ranging from studies of the molecular underpinnings of cancer to focus groups designed to prepare PharmD students for experiential learning.

School of Pharmacy tops pharmacy schools in NIH funding for 39th straight year

Among all U.S. pharmacy schools, the UCSF School of Pharmacy earned the most research funding from the National Institutes of Health in 2018, totaling nearly $29 million dollars that will support studies spanning the basic to the clinical sciences.

Gray receives Krevans Award for outstanding dissertation

Daniel Gray, PhD, is the recipient of the 2011 Julius R. and Patricia A. Krevans Distinguished Dissertation Award. The award, which honors the most outstanding doctoral dissertation by graduate department nominees who completed their PhDs at UCSF during the past year, is named for UCSF Chancellor...

Ortiz de Montellano named associate dean

Paul Ortiz de Montellano, PhD, is the newly appointed associate dean of research in the UCSF School of Pharmacy. The associate dean of research advises the UCSF School of Pharmacy dean and leaders on research trends, issues, and opportunities and represents the School's research agenda to the...

UCSF technology used to trigger cell death becomes basis of company’s cancer therapy research and development

A technology developed in the laboratory of James Wells, PhD, chair of the Department of Pharmaceutical Chemistry, UCSF School of Pharmacy, will drive a new approach to cancer treatment that switches on or triggers, with small molecules, the enzymes called caspases that promote cell death.

New drug targeted for Kaposi’s sarcoma

A team of scientists from UCSF and colleagues have identified a new potential drug target for the herpes virus that causes Kaposi’s sarcoma. Their research reopens the possibility of using a class of drugs called protease inhibitors, against diseases ranging from cancer to Alzheimer's Disease. This...